Robert P.
- Country
- Poland
- Department
- Vivamed Sp. z o.o.
Research Overview
- Safety Evaluation of SOR102 in Healthy Subjects and Ulcerative Colitis Patients: A Phase I Clinical Trial
- Long-term Safety, Tolerability, and Efficacy of Balinatunfib in Adults with Crohn's Disease or Ulcerative Colitis: A Multicenter Extension Study
- Phase II Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Vixarelimab in Patients with Moderate to Severe Ulcerative Colitis
Data & Insights
Has run more than one trial at 282 of 538 partner sites.
Specializations
Inflammatory Bowel Disease Expertise
The investigator specializes in treating inflammatory bowel conditions, with particular focus on both ulcerative colitis and Crohn's disease across varying levels of severity.
- Moderate to Severe Ulcerative Colitis Management
- Crohn's Disease Treatment Approaches
- Novel Therapeutic Interventions
Demonstrates expertise in evaluating innovative treatment options for patients with inflammatory bowel conditions resistant to conventional therapies.
Therapeutic Innovation
Active involvement in advancing immunological treatments and evaluating novel therapeutic compounds including guselkumab, risankizumab, and other emerging biologics.
- Biologic Response Assessment
- Therapeutic Drug Monitoring
- Long-term Treatment Outcomes
Focuses on investigating both induction and maintenance therapies for chronic inflammatory conditions.
Gastrointestinal Health
Expertise extends to broader gastrointestinal disorders, including investigation of treatments for Clostridioides difficile infection and other digestive system conditions.
- Endoscopic Evaluation
- Clinical Remission Assessment
- Disease Activity Monitoring
Specializes in evaluating therapeutic efficacy through comprehensive clinical and endoscopic assessments.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.